J.B. Chemicals & Pharmaceuticals peers

·Pharma & HealthChart ›

Companies like J.B. Chemicals & Pharmaceuticalslatest year

J.B. Chemicals & PharmaceuticalsJBCHEPHARM · FY26 · this company
Market cap—
P/E—
Sales growth−4.8%
ROE18.7%
Torrent PharmaceuticalsTORNTPHARM · FY26
Open ›
Market cap₹1,54,236
P/E71.29×
Sales growth+50.8%
ROE27.1%
Alkem LaboratoriesALKEM · FY26
Open ›
Market cap₹60,612
P/E26.34×
Sales growth+11.0%
ROE17.8%
Ipca LaboratoriesIPCALAB · FY26
Open ›
Market cap₹48,977
P/E42.92×
Sales growth+20.8%
ROE15.2%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMIPCALABSAILIFENHNEULANDLABACUTAASNATCOPHARM
Comp Set
In ₹ Crore except Per Share
Latest Annual
JBCHEPHARM
FY26
TORNTPHARM
FY26
ALKEM
FY26
IPCALAB
FY26
Peer
Average
Valuation — at last close
P/E—71.29×◆ 26.34×42.92×46.85×
P/B—18.39×◆ 4.39×6.07×9.61×
EV/EBITDA—38.65×◆ 20.06×25.24×27.98×
Market Cap—₹1.54L Cr₹60,612 Cr₹48,977 Cr₹87,942 Cr
Growth
Revenue CAGR 3Y9.61%13.27%8.25%◆ 15.60%12.37% -22%
Revenue CAGR 5Y◆ 15.22%11.80%10.09%12.22%11.37% +34%
Net Income CAGR 3Y20.06%19.75%32.67%◆ 35.20%29.21% -31%
Revenue YoY (latest Q)-4.77%◆ 50.79%10.95%20.76%27.50% -117%
Net Income YoY (latest Q)-30.42%-9.64%-22.00%◆ 82.18%16.85% -281%
Profitability
EBITDA Margin26.70%◆ 32.61%20.43%20.51%24.52% +9%
Net Income Margin◆ 17.10%15.29%15.98%12.27%14.51% +18%
Return on Common Equity18.69%◆ 27.07%17.84%15.20%20.04% -7%
Return on Capital Employed◆ 23.07%14.88%17.59%16.05%16.17% +43%
Return on Assets◆ 15.35%7.21%12.19%9.81%9.74% +58%
Credit & Quality
Total Debt/Equity◆ 0.00×0.84×0.11×0.07×0.34× -100%
Interest Coverage◆ 166.06×8.94×16.32×20.55×15.27× +987%
Scale — latest FY
Revenue / Total Income₹4,148 Cr₹13,980 Cr₹14,712 Cr₹9,646 Cr₹12,780 Cr -68%
Net Income₹709 Cr₹2,138 Cr₹2,351 Cr₹1,184 Cr₹1,891 Cr -62%
Total Assets₹4,969 Cr₹44,312 Cr₹20,873 Cr₹12,370 Cr₹25,852 Cr -81%
EPS₹45.16₹63.92₹192.51₹44.98₹100.47 -55%
Book Value per Share₹258.98₹247.86₹1,156.01₹317.85₹573.91 -55%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.